SpecificationsOrganism/cell line/tissue*Mus musculus*/quadriceps muscleSexMaleSequencer or array typeAffymetrix Mouse Exon 1.0 ST arraysData formatRaw data: CEL. Processed data: SOFT, MINiML, TXT.Experimental factorsGenetically and pharmacologically induced muscular hypertrophy in normal vs. dysferlinopathyExperimental featuresGenome-wide expression analysis comparing hypertrophic changes in normal (*wild-type*, *wt*) and dystrophic (*dysferlin*-deficient, *Dysf*^*−*/*−*^) mouse muscles induced by genetic (follistatin overexpression, *F66*) and pharmacological (administration of activin type II soluble receptor, ACVR2B/Fc) approachesConsentN/ASample source locationN/A

1. Direct link to deposited data {#s0005}
================================

Raw and processed microarray data is available in GEO under accession [GSE62945](ncbi-geo:GSE62945){#ir0015} <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE62945>.GenotypeACVR2B/Fc treatmentReplicateGEO accession URL*wt*No3<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM1536838>\
<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM1536839>\
<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM1536840>*wt*Yes3<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM1536841>\
<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM1536842>\
<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM1536843>*Dysf*^*−*/*−*^No3<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM1536844>\
<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM1536845>\
<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM1536846>*Dysf*^*−*/*−*^Yes3<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM1536847>\
<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM1536848>\
<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM1536849>*F66*No3<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM1536850>\
<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM1536851>\
<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM1536852>*F66*;*Dysf*^*−*/*−*^No3<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM1536853>\
<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM1536854>\
<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM1536855>

2. Experimental design, materials and methods {#s0010}
=============================================

2.1. Study design {#s0015}
-----------------

The identification of myostatin as a negative regulator of skeletal muscle mass raised the possibility that blocking the myostatin signaling could have important applications for treating patients with muscle degenerative diseases [@bb0005]. However, there is one theoretical concern that inducing muscle hypertrophy may cause additional membrane stress, causing further damage to already fragile muscle fibers. To investigate this possibility, we used both genetic and pharmacological approaches to examine the effect of blocking myostatin in *dysferlin* mutant (*Dysf*^*−*/*−*^) mice, which is a model for limb-girdle type 2B and Miyoshi muscular dystrophies. Our rationale was that if myostatin inhibition caused increased membrane damage, these effects would be enhanced in *Dysf*^*−*/*−*^ mice, in which membrane repair is compromised [@bb0010]. For the genetic approach, we used transgenic mice expressing the myostatin inhibitor, follistatin, exclusively in skeletal muscle (*F66* transgenic mice) [@bb0015], and for the pharmacological approach, we used a soluble form of the activin type IIB receptor (ACVR2B) in which the extracellular ligand binding domain was fused to an Fc domain (ACVR2B/Fc) [@bb0020]. Both follistatin and ACVR2B/Fc have been shown to increase muscle mass in mice.

2.2. Mice {#s0020}
---------

To analyze the effect of *F66* in *Dysf*^*−*/*−*^ mice, *F66* transgenic mice were mated with *Dysf*^*−*/*−*^ mice. *F66*;*Dysf*^*+*/*−*^ males from this cross were mated to *Dysf*^*+*/*−*^ females to obtain *F66*;*Dysf*^*−*/*−*^ and *F66*;*Dysf*^*+*/*+*^ (=* F66*) males. Because the *F66* transgene is located on the Y chromosome, we focused all of our analysis on male mice. All mice were maintained on a C57BL/6 background. To analyze the effect of ACVR2B/Fc administration in *Dysf*^*−*/*−*^ mice, male C57BL/6 (*wt*) and *Dysf*^*−*/*−*^ mice beginning at 6 weeks of age were given four weekly intraperitoneal (i.p.) injections of either ACVR2B/Fc (10 mg kg^− 1^, i.e., 200 μg per injection) or PBS.

2.3. Muscle tissues and RNA extraction {#s0025}
--------------------------------------

Total RNA was extracted from quadriceps muscles of 10 week old *wt*, *Dysf*^*−*/*−*^, *F66*, *F66*;*Dysf*^*−*/*−*^, and ACVR2B/Fc-injected *wt* and *Dysf*^*−*/*−*^ mice (6 different groups), and three biological replicates were set up for each group. Quadriceps muscle (100 mg) was homogenized in TRIzol Reagent (Thermo Fisher Scientific Inc., Waltham, MA), and RNA was isolated from the supernatant with the RNeasy Mini Kit (Qiagen Inc., Valencia, CA), according to the manufacturer\'s instructions. All samples were treated with RNase-free DNase set (Qiagen Inc., Valencia, CA) to remove trace amounts of genomic DNA.

2.4. Labeling and hybridization {#s0030}
-------------------------------

The Ambion Expression WT kit (Thermo Fisher Scientific Inc., Waltham, MA) was used to label isolated total RNA, according to the manufacturer\'s manual. The labeled cDNAs were hybridized onto Affymetrix Mouse Exon 1.0 ST arrays (Affymetrix, Inc., Santa Clara, CA) for 17 h at 45 °C with rotation (60 rpm) as described by Affymetrix in their GeneChip Expression Analysis Technical Manual. After washing, the arrays were scanned with Affymetrix\' GeneChip Scanner 3000 7G.

2.5. Data processing {#s0035}
--------------------

Affymetrix CEL files generated by GeneChip Command Console software were extracted and normalized using the Robust Multichip Analysis (RMA) algorithm in Partek Genomics Suite v6.6 software (Partek Inc., St. Louis, USA) [@bb0025]. To ensure exploration of the broadest range of gene transcripts, we imported all 641,130 Affymetrix "Extended Meta-probesets". Quality control assessments were run ([Fig. 1](#f0005){ref-type="fig"}) and these exon-level probesets were summarized into 115,830 transcripts, of which 34,343 currently had annotation at the gene level. As the understanding of genomics and information on the mouse genome increase these values will change over time, with the June 2015 annotation showing 47,252 gene-level transcripts.

Transcription analysis used a single expression value, determined from each transcript\'s exons, for transcript-level comparisons to detect differential gene expression between samples under different conditions. The one-way analysis of variance (ANOVA) was used to determine the magnitude (fold change) and statistical significance (*p*-value) of genes\' changes in expression level between sample classes.

2.6. Data analysis {#s0040}
------------------

Microarray data were visualized by principal components analysis (PCA) mapping, volcano plots, and heat maps [@bb0030]. PCA analysis was performed with the Partek platform, while volcano plots and heat maps were generated with the Spotfire DecisionSite software (TIBCO Software Inc., Boston, MA). Linear regression analyses were performed with Spotfire to compare two different sets of transcriptome changes ([Fig. 2](#f0010){ref-type="fig"}). Gene Ontology (GO; [www.geneontology.org](http://www.geneontology.org){#ir0115}) analysis was conducted for significantly differentially expressed 763 genes (fold change \> 2.0, *p* \< 0.01 in *wt* versus *F66*;*Dysf*^*−*/*−*^) using Spotfire\'s Gene Ontology Browser [@bb0035]. Canonical Pathways, Upstream Regulators, and Network analyses were generated using Ingenuity Pathway Analysis (IPA; QIAGEN Redwood City, CA, USA) and summarized in [Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"}. Myostatin is a transforming growth factor-ß (TGF-ß) family member, and as expected, TGF-ß1 was a top upstream regulator in *F66* mouse muscle (versus *wt*) ([Fig. 3](#f0015){ref-type="fig"}).

3. Conclusion {#s0045}
=============

Collectively, our results demonstrated that *Fst* overexpression and ACVR2B/Fc administration in *dysferlin* mutant mice, a mouse model for limb-girdle type 2B and Miyoshi muscular dystrophies, induced the dramatic changes of gene expression profiling. Our data sets provide a resource for exploring molecular mechanisms that are related to hypertrophy-induced, accelerated muscular degeneration in dysferlinopathy.
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![Microarray quality assessment of 18 chips for three biological replicates in 6 different groups; *wt*, *Dysf*^*−*/*−*^, *F66*, *F66*;*Dysf*^*−*/*−*^, and ACVR2B/Fc-injected *wt* and *Dysf*^*−*/*−*^ mice. (a) Box plots of 18 chips show median-centered raw data distributions. (b) Line graphs of 18 chips also support that all the chips\' probes have signals of similar distribution and median value. (c) The magnitude of between class variation (myostatin inhibition by ACVR2B/Fc and *F66*, and dysferlin deficiency) is compared to that of within-class variation (Error), demonstrating biological variation to be far greater than experimental noise.](gr1){#f0005}

![QQ plots wherein one-way comparisons of transcriptome change are compared between different one-way comparisons. (a) "*wt* versus *Dysf*^*−*/*−*^" and "*wt* with ACVR2B/Fc versus *Dysf*^*−*/*−*^ with ACVR2B/Fc": most of the transcripts that are up-regulated in ACVR2B/Fc-injected *Dysf*^*−*/*−*^ (versus *wt* with ACVR2B/Fc) are also up-regulated in *Dysf*^*−*/*−*^ (versus *wt*). (b) "*wt* versus *Dysf*^*−*/*−*^" and "*F66* versus *F66*;*Dysf*^*−*/*−*^": most of the transcripts are up-regulated only in *F66*;*Dysf*^*−*/*−*^ (versus *F66*). (c) "*F66* versus *F66*;*Dysf*^*−*/*−*^" and "*wt* with ACVR2B/Fc versus *Dysf*^*−*/*−*^ with ACVR2B/Fc": most of the transcripts are up-regulated only in *F66*;*Dysf*^*−*/*−*^ (versus *F66*). As expected, the probe set representing *Dysf* transcripts shows reduced hybridization with RNA from *Dysf*^*−*/*−*^ (versus *wt*), ACVR2B/Fc-injected *Dysf*^*−*/*−*^ (versus *wt* with ACVR2B/Fc), and *F66*;*Dysf*^*−*/*−*^ (versus *F66*) muscles.](gr2){#f0010}

![Ingenuity upstream regulator analysis generated signaling-related networks based on published interactions with the top upstream regulator, TGFb1, in *F66* mouse muscle (versus *wt*) based on our experimental results. Red denotes upregulation, and blue denotes downregulation of the gene. The intensity of the gene color indicates the degree of up- or down-regulation. Orange lines indicate positive regulation, in accordance with the published interaction, blue lines indicate negative regulation, and yellow lines denote changes discordant from published expectation. The networks were generated through the use of Ingenuity Pathway Analysis.](gr3){#f0015}

###### 

Top canonical pathways from Ingenuity Pathway Analysis (IPA).

  Top canonical pathways                                                         *p*-Value    Ratio
  ------------------------------------------------------------------------------ ------------ ----------------
  *wt* versus ACVR2B/Fc-injected *wt*                                                         
  Leptin signaling in obesity                                                    1.14E − 03   10/84 (0.119)
  Cardiac β-adrenergic signaling                                                 1.73E − 03   14/158 (0.089)
  G-protein coupled receptor signaling                                           5.04E − 03   20/275 (0.073)
  AMPK signaling                                                                 6.66E − 03   13/169 (0.077)
  Serotonin receptor signaling                                                   6.79E − 03   6/46 (0.130)
                                                                                              
  *Dysf*^*−*/*−*^ versus ACVR2B/Fc-injected *Dysf*^*−*/*−*^                                   
  PI3K/AKT signaling                                                             5.37E − 03   10/144 (0.069)
  14-3-3-mediated signaling                                                      9.88E − 03   9/121 (0.074)
  Role of Oct4 in mammalian embryonic stem cell pluripotency                     1.1E − 02    5/45 (0.111)
  Assembly of RNA polymerase ii complex                                          1.69E − 02   5/56 (0.089)
  Complement system                                                              1.84E − 02   4/35 (0.114)
                                                                                              
  ACVR2B/Fc-injected *wt* versus ACVR2B/Fc-injected *Dysf*^*−*/*−*^                           
  IL-10 signaling                                                                6.78E − 04   9/78 (0.115)
  Hepatic fibrosis/hepatic stellate cell activation                              8.53E − 04   13/146 (0.089)
  TREM1 signaling                                                                8.67E − 04   8/71 (0.113)
  Granulocyte adhesion and diapedesis                                            8.78E − 04   15/178 (0.084)
  Altered T cell and B cell signaling in rheumatoid arthritis                    2.42E − 03   9/92 (0.098)
                                                                                              
  *wt* versus *F66*                                                                           
  Hepatic fibrosis/hepatic stellate cell activation                              3.68E − 07   22/146 (0.151)
  Inhibition of matrix metalloproteases                                          1.22E − 06   11/40 (0.275)
  Glioma invasiveness signaling                                                  3.21E − 04   10/61 (0.164)
  Granulocyte adhesion and diapedesis                                            4.49E − 04   19/178 (0.107)
  Coagulation system                                                             9.15E − 04   7/38 (0.184)
                                                                                              
  *Dysf*^*−*/*−*^ versus *F66*;*Dysf*^*−*/*−*^                                                
  Hepatic fibrosis/hepatic stellate cell activation                              6.25E − 16   36/146 (0.247)
  Fcγ receptor-mediated phagocytosis in macrophages and monocytes                9.52E − 15   29/102 (0.284)
  Granulocyte adhesion and diapedesis                                            5.89E − 12   35/178 (0.197)
  Agranulocyte adhesion and diapedesis                                           6.81E − 12   36/189 (0.190)
  Leukocyte extravasation signaling                                              5.06E − 10   35/207 (0.169)
                                                                                              
  *F66* versus *F66*;*Dysf*^*−*/*−*^                                                          
  Fcγ receptor-mediated phagocytosis in macrophages and monocytes                2.4E − 13    26/102 (0.255)
  Dendritic cell maturation                                                      1.82E − 10   31/209 (0.148)
  Leukocyte extravasation signaling                                              3.53E − 10   33/207 (0.159)
  Role of pattern recognition receptors in recognition of bacteria and viruses   3.7E − 10    22/106 (0.208)
  Hepatic fibrosis/hepatic stellate cell activation                              1.09E − 09   26/146 (0.178)

###### 

Top upstream regulators from IPA.

  Top upstream regulators                                             *p*-Value of overlap   Predicted activation state
  ------------------------------------------------------------------- ---------------------- ----------------------------
  *wt* versus ACVR2B/Fc-injected *wt*                                                        
  TNF                                                                 4.60E − 08             
  miR-141-3p (and other miRNAs w/seed AACACUG)                        3.43E − 07             
  Lipopolysaccharide                                                  5.11E − 07             
  Dexamethasone                                                       9.34E − 07             
  GW501516                                                            1.14E − 06             
                                                                                             
  *Dysf*^*−*/*−*^ versus ACVR2B/Fc-injected *Dysf*^*−*/*−*^                                  
  miR-27a-3p (and other miRNAs w/seed UCACAGU)                        1.78E − 06             
  miR-128-3p (and other miRNAs w/seed CACAGUG)                        1.99E − 06             
  DYSF                                                                6.04E − 06             
  miR-874-3p (and other miRNAs w/seed UGCCCUG)                        1.29E − 05             
  miR-344d-3p (and other miRNAs w/seed AUAUAAC)                       3.15E − 04             
                                                                                             
  ACVR2B/Fc-injected *wt* versus ACVR2B/Fc-injected *Dysf*^*−*/*−*^                          
  DYSF                                                                1.42E − 22             
  Lipopolysaccharide                                                  1.32E − 20             Activated
  IL1B                                                                1.15E − 17             Activated
  TNF                                                                 2.06E − 17             Activated
  IL6                                                                 1.47E − 13             Activated
                                                                                             
  *wt* versus *F66*                                                                          
  TGFB1                                                               8.48E − 25             Activated
  IL1B                                                                3.48E − 22             Activated
  TNF                                                                 2.18E − 20             Activated
  Lipopolysaccharide                                                  2.88E − 20             Activated
  Dexamethasone                                                       7.91E − 17             
                                                                                             
  *Dysf*^*−*/*−*^ versus *F66*;*Dysf*^*−*/*−*^                                               
  Lipopolysaccharide                                                  2.80E − 58             Activated
  IFNG                                                                1.31E − 41             Activated
  TNF                                                                 1.32E − 39             Activated
  TGFB1                                                               1.57E − 39             Activated
  DYSF                                                                2.23E − 32             
                                                                                             
  *F66* versus *F66*;*Dysf*^*−*/*−*^                                                         
  lipopolysaccharide                                                  1.12E − 44             Activated
  TGFB1                                                               7.23E − 36             Activated
  IFNG                                                                8.84E − 35             Activated
  DYSF                                                                3.05E − 34             
  TNF                                                                 5.02E − 34             Activated

###### 

Top networks from IPA.

  Top networks                                                                                                          Score
  --------------------------------------------------------------------------------------------------------------------- -------
  *wt* versus ACVR2B/Fc-injected *wt*                                                                                   
  Cell-mediated immune response, cellular development, cellular function and maintenance                                65
  Hematological system development and function, infectious disease, cell-mediated immune response                      54
  Gene expression, cell cycle, DNA replication, recombination, and repair                                               49
  Cell signaling, molecular transport, vitamin and mineral metabolism                                                   47
  Lipid metabolism, molecular transport, small molecule biochemistry                                                    43
                                                                                                                        
  *Dysf*^*−*/*−*^ versus ACVR2B/Fc-injected *Dysf*^*−*/*−*^                                                             
  Hematological system development and function, gene expression, RNA post-transcriptional modification                 87
  Cellular compromise, molecular transport, nucleic acid metabolism                                                     58
  Cellular development, skeletal and muscular system development and function, cellular movement                        52
  Humoral immune response, protein synthesis, cell-to-cell signaling and interaction                                    52
  Cardiovascular disease, cell morphology, cellular function and maintenance                                            51
                                                                                                                        
  ACVR2B/Fc-injected *wt* versus ACVR2B/Fc-injected *Dysf*^*−*/*−*^                                                     
  Increased levels of hematocrit, increased levels of red blood cells, inflammatory response                            61
  Cancer, cellular development, cellular growth and proliferation                                                       60
  Carbohydrate metabolism, lipid metabolism, small molecule biochemistry                                                53
  Hematological system development and function, tissue morphology, inflammatory response                               47
  Developmental disorder, hereditary disorder, immunological disease                                                    46
                                                                                                                        
  *wt* versus *F66*                                                                                                     
  Small molecule biochemistry, cancer, gastrointestinal disease                                                         70
  RNA post-transcriptional modification, organismal development, renal and urological system development and function   63
  Cellular movement, connective tissue disorders, cardiovascular disease                                                53
  Lipid metabolism, small molecule biochemistry, molecular transport                                                    52
  Cell cycle, cardiovascular system development and function, embryonic development                                     50
                                                                                                                        
  *Dysf*^*−*/*−*^ versus *F66*;*Dysf*^*−*/*−*^                                                                          
  Inflammatory response, cardiovascular system development and function, cardiovascular disease                         58
  Cancer, gastrointestinal disease, hepatic system disease                                                              58
  Connective tissue disorders, cellular assembly and organization, cellular function and maintenance                    54
  Cellular development, small molecule biochemistry, cell cycle                                                         54
  Cellular movement, hematological system development and function, immune cell trafficking                             51
                                                                                                                        
  *F66* versus *F66*;*Dysf*^*−*/*−*^                                                                                    
  Cellular assembly and organization, cell-to-cell signaling and interaction, cell death and survival                   84
  Cellular assembly and organization, cell cycle, connective tissue development and function                            59
  Cancer, reproductive system disease, neurological disease                                                             55
  Connective tissue disorders, dermatological diseases and conditions, developmental disorder                           48
  Cancer, dermatological diseases and conditions, hematological disease                                                 48
